Peritoneal Surface Malignancy
Conditions
Brief summary
The primary objective of this open-label, Phase I, trial is to evaluate the toxicity profile of intraperitoneal talimogene laherparepvec (TVEC) in patients with peritoneal surface dissemination from gastrointestinal or recurrent, platinum-resistant ovarian tumors. The secondary objectives are to evaluate the pharmacokinetic profile and viral shedding of TVEC by measuring viral load in serum and urine as well as viral load in peritoneal washings.
Detailed description
This is a non-randomized, open-label Phase I trial in patients with Stage IV peritoneal surface dissemination from gastrointestinal or recurrent, platinum-resistant ovarian tumors enrolled at Duke Cancer Institute. All subjects will complete an extensive medical history, baseline physical examination and clinical assessment to ensure subject eligibility requirements within 4 weeks of starting study drug. All eligible patients must have a peritoneal catheter placed at least 2 weeks prior to the initiation of therapy. All patients will receive an initial loading dose of TVEC 4x10\^6 Plaque Forming Units (PFU) on Cycle 1 Day 1 to enable the formation of protective antibodies as described in the currently approved treatment protocol for the treatment of cutaneous melanoma. Three weeks after the initial loading dose, patients will receive TVEC at the dose level for the cohort for which they are enrolled every 2 weeks for up to 4 doses. The length of the first cycle is 5 weeks and subsequent cycles are 2 weeks in duration. The first portion of the study, the Dose Escalation cohort, will evaluate the toxicity profile of TVEC in patients with peritoneal surface dissemination from gastrointestinal or recurrent, platinum-resistant ovarian tumors. Using a standard '3+3' dose escalation design, there are up to three dose levels that may be explored. Dose escalation will be dependent on dose-limiting toxicity (DLT) within the cohorts. Once the maximum tolerated dose (MTD) has been determined, an additional 6 subjects will be enrolled to the dose expansion cohort. All subjects will receive an initial loading dose of TVEC 4x10\^6 PFU on Cycle 1 Day 1. Three weeks after the initial loading dose, patients will receive TVEC at the MTD every 2 weeks for up to 4 doses. The length of the first cycle is 5 weeks and the subsequent cycles are 2 weeks in duration. There are a total of four cycles.
Interventions
BIOLOGICALTalimogene Laherparepvec
TVEC is an oncolytic, genetically modified virus designed to reproduce in tumor tissue and stimulate your immune system to attack the tumor cells
Sponsors
Dan Blazer III, M.D.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
1. Patients must have stage IV peritoneal surface dissemination of gastrointestinal cancer or recurrent ovarian, fallopian tube or primary peritoneal cancer with metastatic disease to the peritoneum that cannot be completely resected at time of abdominal exploration. Please note: 1. Locoregional extension of peritoneal disease beyond the peritoneal cavity (including but not limited to the pleura and subcutaneous soft tissue) is permitted with PI approval, 2. Radiographically measurable disease is preferable, but for patients with previously documented gastrointestinal, fallopian tube, ovarian, or primary peritoneal cancer, for whom relevant tumor markers (including but not limited to CEA, CA 19-9 or CA-125) have been useful markers of disease progression and/or response to treatment, an elevated relevant tumor marker (including but not limited to CEA, CA 19-9 or CA-125) above the institutional upper limit of normal could be substituted for radiographic imaging, 3. Asymptomatic primary tumors are permitted. 2. Subjects must have had at least one prior round of systemic therapy or have refused or be ineligible for standard systemic therapy for their disease type. No prior systemic therapy is required for low grade mucinous cancers. 3. Age ≥ 18 years 4. Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-2 5. Adequate marrow function as evidenced by: 1. Absolute neutrophil count (ANC) ≥ 2,000/µL 2. Platelets ≥ 100,000/µL 3. Hemoglobin (Hgb) ≥ 9 g/dL 6. Adequate renal function as evidenced by serum creatinine ≤ 1.5 x upper limit of normal (ULN), OR 24-hour creatinine clearance ≥ 60 mL/min for subject with creatinine levels \> 1.5 x ULN. 7. Adequate hepatic function as evidenced by: 1. Serum bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for a subject with total bilirubin level \> 1.5 x ULN 2. Aspartate aminotransferase (AST) ≤ 3 x ULN 3. Alanine aminotransferase (ALT) ≤ 3 x ULN 4. Alkaline phosphatase ≤ 3 x ULN 8. INR or PT ≤ 1.5 x ULN, unless the subject is receiving anticoagulant therapy, in which case PT and PTT/aPTT must be within therapeutic range of intended use of anticoagulants (and may need to be held per institutional standards for placement of the Bard peritoneal catheter). 9. Patients must be recovered from both acute and late effects of any prior surgery, radiotherapy or other antineoplastic therapy. 10. Patients of reproductive potential (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) at the time of pregnancy test (women of childbearing potential only), during the course of the study and for 90 days after the last dose of study drug, even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of study and for 90 days after the last dose of study drug. 11. Patients or their legal representatives must be able to read, understand and provide informed consent to participate in the trial.
Exclusion criteria
1. Prior chemotherapy, radiotherapy, biological cancer therapy, targeted therapy, or major surgery within 28 days prior to enrollment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 28 days prior to enrollment. 2. Patients who received radiotherapy to more than 25% of their bone marrow. 3. Currently receiving treatment with another investigational device or drug study, or \< 30 days since ending treatment with another investigational device or drug study(s). Other investigational procedures while participating in this study are excluded. 4. Known active central nervous system (CNS) metastases. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids \>10 mg/day of prednisone or equivalent. The exception does not include carcinomatous meningitis, which is excluded regardless of clinical stability. 5. Metastatic disease in a site other than the peritoneal surfaces. Note: Locoregional extension of peritoneal disease may be permitted with PI approval. 6. History or evidence of active autoimmune disease that requires systemic treatment (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. 7. Evidence of clinically significant immunosuppression such as the following: 1. Primary immunodeficiency state such as Severe Combined Immunodeficiency Disease. 2. Concurrent opportunistic infection. 3. Receiving systemic immunosuppressive therapy (\> 2 weeks) including oral steroid doses \>10mg/day of prednisone or equivalent within 7 days prior to enrollment. 8. History of allogenic organ or hematopoietic transplant. 9. Active herpes simplex virus (HSV) that requires intermittent or chronic systemic anti-herpetic therapy or prior complications of herpetic infection, e.g. herpetic keratitis or encephalitis. 10. Requiring intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (e.g., acyclovir), other than intermittent topical use. 11. Prior treatment with talimogene laherparepvec or any other oncolytic virus. 12. Subject has known sensitivity to talimogene laherparepvec or any of its components to be administered during dosing. 13. Prior therapy with tumor vaccine. 14. Receipt of a live vaccine within 28 days prior to enrollment. 15. Known to have acute or chronic active hepatitis B or C infection (active, previously treated, or both). 16. Known history of HIV infection. 17. Active infection or fever ≥ 101.3°F within 3 days of the first scheduled day of protocol treatment. 18. Peripheral neuropathy ≥ Grade 2. 19. Bleeding disorders that would preclude intraperitoneal port placement. 20. Refractory ascites that requires palliative paracentesis more frequently than once a month. Any other medical condition, including mental illness or substance abuse, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study or interferes with the interpretation of the results. 21. History of other malignancy within the past 5 years. 22. Female subjects who are pregnant or breast-feeding, or planning to become pregnant during study treatment or through 90 days after the last dose of talimogene laherparepvec. 23. Subjects of childbearing potential who are unwilling to use acceptable method(s) of effective contraception during study treatment and through 90 days after the last dose of talimogene laherparepvec. 24. Sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 90 days after treatment with talimogene laherparepvec.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose Limiting Toxicity (DLT) | from start of treatment until 30-day follow-up visit, up to 14 weeks | Number of participants who experienced a dose limiting toxicity (DLT) |
Countries
United States
Participant flow
Recruitment details
Subjects were recruited at 3 sites (Duke University Medical Center, University of Illinois at Chicago, and Wake Forest Baptist Medical Center).
Pre-assignment details
28 subjects signed the consent form. 9 failed screening and were withdrawn from the study. 1 voluntarily withdrew from the study before getting the study drug. 18 of them received the study drug and are considered evaluable subjects.
Participants by arm
| Arm | Count |
|---|---|
| Dose Level 1 4 x 10\^6 PFU of talimogene laherparepvec. | 3 |
| Dose Level 2 4 x 10\^7 PFU of talimogene laherparepvec. | 4 |
| Dose Level 3 4 x 10\^8 PFU of talimogene laherparepvec. | 11 |
| Total | 18 |
Baseline characteristics
| Characteristic | Dose Level 1 | Dose Level 2 | Dose Level 3 | Total |
|---|---|---|---|---|
| Age, Continuous | 68.0 years STANDARD_DEVIATION 4.9 | 56.5 years STANDARD_DEVIATION 11 | 61.2 years STANDARD_DEVIATION 7.2 | 61.3 years STANDARD_DEVIATION 8.7 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 3 Participants | 11 Participants | 17 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 3 Participants | 3 Participants | 9 Participants | 15 Participants |
| Sex: Female, Male Female | 2 Participants | 1 Participants | 7 Participants | 10 Participants |
| Sex: Female, Male Male | 1 Participants | 3 Participants | 4 Participants | 8 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 3 / 3 | 4 / 4 | 5 / 11 |
| other Total, other adverse events | 3 / 3 | 3 / 4 | 10 / 11 |
| serious Total, serious adverse events | 1 / 3 | 2 / 4 | 3 / 11 |
Outcome results
Primary
Dose Limiting Toxicity (DLT)
Number of participants who experienced a dose limiting toxicity (DLT)
Time frame: from start of treatment until 30-day follow-up visit, up to 14 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| TVEC Dose of 4x10^6 PFU (Plaque-forming Units) | Dose Limiting Toxicity (DLT) | 0 Participants |
| TVEC Dose of 4x10^7 PFU (Plaque-forming Units) | Dose Limiting Toxicity (DLT) | 0 Participants |
| TVEC Dose of 4x10^8 PFU (Plaque-forming Units) | Dose Limiting Toxicity (DLT) | 0 Participants |